News brief­ing: Cosen­tyx shows ear­ly pos­i­tive signs in pso­ri­at­ic arthri­tis; Pfiz­er's PhI­Ib for car­dio drug trig­gers $75M mile­stone

No­var­tis’ block­buster Cosen­tyx is seek­ing ap­proval in an­oth­er in­di­ca­tion, and the com­pa­ny re­port­ed pos­i­tive ear­ly Phase II­Ib re­sults Thurs­day.

Look­ing to re­duce joint lin­ing in­flam­ma­tion in pso­ri­at­ic arthri­tis, Cosen­tyx saw ben­e­fits against place­bo af­ter 12 weeks. Though No­var­tis didn’t pro­vide any num­bers in this ear­ly look, the com­pa­ny said the drug showed “sig­nif­i­cant ben­e­fit” on its way to meet­ing the pri­ma­ry end­point.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.